Healthtech funding in Southeast Asia is experiencing a downward trend that began a few years ago, right after the COVID-19 pandemic hit the area. According to the SEA HealthTech and Life Sciences Annual Funding Report 2024 by insights firm Tracxn Technologies Ltd, the region is facing its worst funding year in seven years. This slump contrasts with its peak capital raising statistics from 2021, representing the sector’s best year.
For example, even though the startup ecosystem for healthtech in Southeast Asia has 3,600 companies, only 322 received investment capital last year. Total funding was USD 123 million, a significant 79% drop from USD 599 million in 2023. In addition, 2024’s amount represented an equally substantial 90% decrease from the money raised in 2022.
We explore the impact of telemedicine in healthtech in Southeast Asia
These figures show a downtrend in the region, reflecting the broader Asian trends, which show that investors were not as keen to pump money into Asia as they had been in previous years. In contrast, healthtech funding in other areas, like the USA and Europe, grew from its 2023’s numbers.
Over the years, the healthcare landscape in the Association of Southeast Asian Nations (ASEAN) has seen startups, such as HealthifyMe, Halodoc, Doctor Anywhere, and Speedoc, develop innovative medical solutions. Moreover, regulatory changes and infrastructure investments have enhanced the sector and inspired the emergence of more founders in this industry.
Despite the encouraging signs of growth, what factors contribute to the reduced capital investment in ASEAN?
Reasons for the funding decline in the healthtech sector
The strong demand for healthtech in Southeast Asia is due to its positive impact on the region. It brings convenience through timely medical interventions, makes treatment available to rural area residents, provides remote symptom-monitoring technology, and improves the quality of care and outcomes for patients.
Global economic slowdowns
The global economy has gone through headwinds, such as high interest rates, inflation, recession, and rising energy costs. Geopolitical tensions have also contributed to the slowdown in funding, with the political instability affecting markets and company valuations. In turn, these issues have caused venture capital (VC) firms to have to do more to raise funds to back startups in ASEAN.
High-growth sectors like fintech, blockchain, and cleantech are receiving a lot of funds, reducing the amount left behind for healthtech.
Investor caution
According to the Tracxn report, investors are more cautious about where they invest their money. Singapore received the bulk of the funding at 75%, followed by Indonesia, Vietnam, and Malaysia. Investors have also been focusing on startups with ESG policies (Environmental, Social, and Governance) to ensure the companies protect the environment as they manufacture their goods and packages or offer services to customers.
Market saturation
As the region digitalises its industries, similar healthtech products have oversaturated the market. For example, fitness wearables are widespread, with many people keen to monitor their health, record their workouts, and analyse their sleep and wellness data at all times.
Thus, investors are unlikely to be excited about pumping money into the same markets. Tracxn reported that Employee Health IT, Neurology, and Fitness & Wellness Tech were the top-funded healthtech segments in 2024, while areas like mental health require more investment.
Service pricing
Finally, technology costs remain high, making digital health services expensive. ASEAN governments can reduce prices by subsidising healthcare costs to ensure startups deliver cost-effective tech solutions.
Overall, the lack of funding means healthtech startups do not have enough cash flow to invest in research and development (R&D) and innovate quality products and services. It also means companies cannot attract the best talent in the market, exposing themselves to poor results and mishandled patient data. Moreover, expanding the business will be challenging without capital.
Opportunities for healthtech startups in Southeast Asia
Even though healthtech funding in Southeast Asia is facing some downturn, the sector offers several opportunities to consolidate its foundations and set it up for future success. For example, startups will be able to attract more investors by focusing on technological advances in wearables, sensor tech, data storage, health monitors, communication platforms, and more. The best new hardware will make the industry more effective, improve health outcomes, and earn companies substantial profits ethically.
Secondly, AI and GenAI-powered tools will continue receiving healthtech funding because they help with disease detection, symptom analysis, and health data storage and processing. Furthermore, its communications solutions, like chatbots, ensure doctors always attend to patients on time 24/7.
Healthtech in Southeast Asia will thrive if startups adopt sustainable business models, tailor their solutions to the market, and learn how to inspire investors to fund them. Ultimately, there might be a few more bumps due to geopolitical considerations, but those should not distract healthcare stakeholders from evolving the sector to benefit the people.